Oleclumab

Drug Overview

Oleclumab (also known by its developmental code MEDI9447) is an investigational, human monoclonal antibody designed to target and inhibit the CD73 enzyme (also known as ecto-5′-nucleotidase). CD73 is a cell-surface enzyme that is highly overexpressed in several types of solid tumors, where it plays a critical role in creating a “pro-tumor” environment by suppressing the immune system.

In the clinical landscape of March 2026, oleclumab is recognized as a pioneer in “Adenosine Pathway Inhibition.” In many aggressive cancers, the tumor uses CD73 to convert “danger signals” (ATP) into “silencing signals” (adenosine). By blocking CD73, oleclumab prevents the buildup of adenosine, effectively “re-awakening” the immune system so that T-cells can recognize and attack the cancer. It is primarily being studied in combination with immune checkpoint inhibitors (like durvalumab) and chemotherapy to treat cancers that have traditionally been resistant to immunotherapy.

• Generic Name: Oleclumab.
• Code Name: MEDI9447.
• Drug Class: Anti-CD73 Monoclonal Antibody; Immunotherapy.
• Mechanism: Selective inhibition of the CD73 enzyme to reduce immunosuppressive adenosine levels.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, oleclumab is not FDA-approved. It has been granted Breakthrough Therapy Designation for certain combinations in non-small cell lung cancer (NSCLC) and is currently being evaluated in Phase 2 and Phase 3 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Oleclumab works by disrupting a “metabolic shield” that cancer cells use to survive.

1. The CD73/Adenosine Pathway

In a healthy body, the molecule ATP signals “danger” and activates the immune system. However, tumors overexpress the enzyme CD73, which acts like a “converter.”

• Metabolic Conversion: CD73 converts AMP (adenosine monophosphate) into adenosine.
• Immune Suppression: Adenosine binds to receptors on T-cells and Natural Killer (NK) cells, telling them to “shut down” and stop attacking the tumor.

2. Blocking the “Converter”

Oleclumab is an antibody that binds to a specific part of the CD73 protein.

• Allosteric Inhibition: By binding to CD73, oleclumab prevents the enzyme from folding correctly into its active state. This stops the production of adenosine.
• Internalization: The binding of oleclumab can also cause the CD73 protein to be pulled inside the cell and destroyed, permanently removing the enzyme from the tumor surface.

3. Reversing Immune Exhaustion

Without high levels of adenosine in the tumor microenvironment, the “brakes” on the immune system are released.

• T-Cell Activation: T-cells can once again multiply and release toxins to kill the cancer cells.
• Synergy: This makes oleclumab an ideal partner for PD-1/PD-L1 inhibitors (like durvalumab), as the two drugs work together to attack the tumor from different angles.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for oleclumab.

Clinical research through 2026 has focused on its potential in several “adenosine-high” cancers:

• Non-Small Cell Lung Cancer (NSCLC): Studied in the COAST trial and PACIFIC-9 Phase 3 trial as a maintenance therapy after chemo-radiation.
• Pancreatic Adenocarcinoma: Investigated in combination with chemotherapy and durvalumab, as pancreatic tumors are known for having extremely high CD73 levels and dense “adenosine shields.”
• Advanced Prostate Cancer: Evaluated for its ability to sensitize “cold” prostate tumors to immunotherapy.
• Colorectal Cancer (MSS): Studied in patients with “microsatellite stable” tumors, which are generally resistant to standard immunotherapies.

Dosage and Administration Protocols

As an investigational drug, oleclumab dosing is strictly managed within clinical trials (such as the PACIFIC-9 study).

Clinical Efficacy and Research Results

As of early 2026, results from the Phase 2 COAST trial and early Phase 3 data have provided significant biological proof-of-concept:

• PFS Improvement: In patients with Stage III NSCLC, the combination of durvalumab and oleclumab showed a significantly longer Progression-Free Survival (PFS) compared to durvalumab alone (35% vs 18% at 10 months).
• Objective Response Rate: In several solid tumor trials, the addition of oleclumab doubled the number of patients who saw their tumors shrink compared to those on single-agent immunotherapy.
• Biomarker Evidence: Clinical data has confirmed that the drug successfully reduces adenosine levels in the tumor, proving it is hitting its intended metabolic target in patients.

Safety Profile and Side Effects

The safety profile of oleclumab is generally favorable, as the drug does not cause significant “generalized” immune activation like some other therapies.

Common Side Effects (>20%):

• Fatigue: General systemic tiredness, manageable with rest.
• Infusion-Related Reactions: Mild fever, chills, or headache shortly after the infusion.
• Pruritus (Itching): Often mild skin irritation.
• Gastrointestinal: Mild nausea or diarrhea.

Serious Risks:

• Immune-Mediated Adverse Events (irAEs): When combined with durvalumab, there is a risk of the immune system attacking healthy organs (e.g., pneumonitis, colitis, or thyroiditis).
• Stomatitis: Inflammation of the mouth and lips, seen in some NSCLC patients.
• Hepatotoxicity: Rare elevations in liver enzymes, requiring regular monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, oleclumab is being used to study “Metabolic Reprogramming.” Researchers are investigating how CD73-derived adenosine affects the “quiescence” (resting state) of Hematopoietic Stem Cells and whether blocking this pathway can help the bone marrow recover faster from chemotherapy. In 2026, there is also intense focus on “Oral CD73 Inhibitors.” Scientists are comparing the “long-acting” antibody oleclumab with newer small-molecule pills to see which method is more effective at maintaining a “zero-adenosine” environment in the tumor. Furthermore, studies are exploring the use of oleclumab in combination with radiation, as radiation is known to cause a surge in ATP, which tumors quickly try to convert into immunosuppressive adenosine.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• CD73 Biomarker Testing: While not always required, some trials look for tumors with high CD73 expression as a marker for potential success.
• Baseline Blood Work: Comprehensive CBC, liver function, and thyroid function (TSH) tests.

“Do’s and Don’ts” List:

• DO report any new “shortness of breath” or a “new cough” immediately, as these can be early signs of pneumonitis, especially when combined with other immunotherapies.
• DO keep your “Immunity Wallet Card” with you; emergency doctors need to know you are on an immune-modulating therapy.
• DON’T take any new over-the-counter “immune boosters” (like high-dose Vitamin C or Elderberry) without consulting your oncologist, as they may interfere with the metabolic balance the drug is trying to achieve.
• DON’T ignore persistent diarrhea; while it can be mild, in immunotherapy it can sometimes progress to a more serious condition called colitis.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Oleclumab (MEDI9447) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.